Latest Insider Transactions at Viracta Therapeutics, Inc. (VIRX)
This section provides a real-time view of insider transactions for Viracta Therapeutics, Inc. (VIRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Viracta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Viracta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
14,635
-2.43%
|
$29,270
$2.78 P/Share
|
|
Feb 25
2022
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+7.94%
|
-
|
|
Feb 25
2022
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+25.0%
|
-
|
|
Feb 25
2022
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,127
+8.83%
|
-
|
|
Feb 25
2022
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+4.01%
|
-
|
|
Dec 29
2021
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+1.2%
|
$0
$0.9 P/Share
|
|
Nov 29
2021
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
15,833
-2.7%
|
$63,332
$4.82 P/Share
|
|
Nov 29
2021
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
4,325
-5.6%
|
$17,300
$4.82 P/Share
|
|
Nov 29
2021
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,591
-6.31%
|
$10,364
$4.82 P/Share
|
|
Nov 26
2021
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
11,914
-1.99%
|
$47,656
$4.8 P/Share
|
|
Nov 26
2021
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,254
-4.04%
|
$13,016
$4.8 P/Share
|
|
Nov 26
2021
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,950
-4.53%
|
$7,800
$4.8 P/Share
|
|
Nov 25
2021
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
50,437
+7.77%
|
-
|
|
Nov 25
2021
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,777
+14.61%
|
-
|
|
Nov 25
2021
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,254
+16.1%
|
-
|
|
Nov 25
2021
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
18,068
+50.0%
|
-
|
|
Nov 15
2021
|
Ivor Royston |
BUY
Open market or private purchase
|
Direct |
8,000
+1.44%
|
$40,000
$5.56 P/Share
|
|
Sep 28
2021
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.03%
|
$0
$0.9 P/Share
|
|
May 28
2021
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+17.45%
|
$0
$0.9 P/Share
|
|
May 11
2021
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,750
+27.8%
|
$69,500
$2.42 P/Share
|
|
Nov 06
2017
|
Mpm Oncology Impact Management Gp LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,200
+0.48%
|
$32,400
$2.77 P/Share
|
|
Nov 03
2017
|
Mpm Oncology Impact Management Gp LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.19%
|
$80,000
$2.89 P/Share
|
|
Nov 02
2017
|
Mpm Oncology Impact Management Gp LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,300
+0.77%
|
$50,600
$2.59 P/Share
|